Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioStock Break Out Watch List Initiated with ACAD, AMRN and CELG

ACAD
BioStock Break Out Watch List Initiated with ACAD, AMRN and CELG

New York, NY -- (ACCESSWIRE) -- 04/11/2013 -- Growing Stock Report initiates a NASDAQ BioStock Watch List adding ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Amarin Corporation plc (NASDAQ:AMRN), Gilead Sciences Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG).

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares are continuing their trend higher after the company said it will seek early approval of its pimavanserin drug for the treatment of Parkinson's disease. It will no longer carry out an additional phase III trial that was slated to begin this month. Analyst at Piper Jaffray upgraded its rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) from Neutral to Overweight. As of this writing, Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) are currently up (+68.27%) which has prompted Growing Stock Report to add the stock to their NASDAQ BioStock Watch List and Investor Poll.

To see what other Investors are saying about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=ACAD&SubId=AW

Amarin Corporation plc (NASDAQ:AMRN) shares are up (+6.16%) on over 3.6 million shares traded after earlier this week announcing that additional data from its phase 3 clinical trials of its Vascepa (icosapent ethyl) drug revealed that it achieved reductions in Apo C-III levels of 25.1 percent (p<0.0001) and 19.2 percent (p<0.0001) compared to placebo, respectively. The lipoprotein Apo C-III is thought to inhibit the clearance of triglycerides from the blood. People who do not produce Apo C-III have lower levels of triglycerides and lower instances of cardiovascular disease. “Amarin is proud of the robust performance of Vascepa in the MARINE and ANCHOR studies,” said Steven B. Ketchum, Ph.D., President of Research and Development of Amarin. This increase in the stock price and volume has prompted Growing Stock Report to add Amarin Corporation plc (NASDAQ:AMRN) to their NASDAQ BioStock Watch List and Investor Poll.

To see what other Investors are saying about Amarin Corporation plc (NASDAQ:AMRN)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=AMRN&SubId=AW

Also Mentioned in their NASDAQ BioStock Watch List Report was: Gilead Sciences Inc. (NASDAQ:GILD), Celgene Corporation (NASDAQ:CELG), Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and Sarepta Therapeutics, Inc. (NASDAQ:SRPT).

To see what other Investors are saying about: GILD, CELG, ONXX and SRPT

Click Here: http://www.growingstockreport.com/PR.aspx?stock=GILD-CELG-ONXX SRPT&Subid=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com